If you enjoy this content, please share it with a colleague
ProTom International
RELATED CONTENT
ProTom International received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radiance 330 ...
As one of the more precise methods of delivering radiation therapy for cancer treatment, proton therapy has grown at a rapid pace the last several years. Considered experimental not too long ago and used primarily in research settings, clinicians across the globe are rapidly coming to accept the utility of proton therapy for numerous indications — a list that many expect to continue to grow rapidly.
October 24, 2017 — ProTom International Holding Co. announced that it has signed a contract for the purchase and ...
The global proton therapy market hit a major milestone in 2015, eclipsing the billion-dollar mark for sales orders and more than doubling the previous year’s total, according to market intelligence firm Medraysintell. This boom was evidenced by new proton therapy centers springing up all over the world, including 11 just since November 2015 — eight in the United States and three abroad in Hong Kong, Belgium and the Netherlands.
ProTom International announced its accelerated focus on the installation of its Radiance 330 proton therapy system to be housed in the Massachusetts General Hospital ("MGH") Department of Radiation Oncology. For the first time, advanced scanning-beam technology is being installed inside a radiation-shielded vault embedded within an existing, operational radiation oncology department — a solution that enables the facility to share clinical staff, ancillary equipment and patient support areas.
Incidents of cancer are on the rise globally. According to a press release from the World Health Organization’s (WHO) International Agency for Research on Cancer (IARC), “In 2012, the worldwide burden of cancer rose to an estimated 14 million new cases per year, a figure expected to rise to 22 million annually in the next decade.” As the numbers increase around the world, research continues to unveil unconventional options for cancer treatment. Over the past five years, proton therapy has emerged as one popular choice. Hailed by some as the Rolls Royce of radiation oncology, the technology’s precision and accuracy, along with its ability to prevent damage to critical structures and healthy tissues, has made it a technology that many vendors and healthcare facilities are actively investing in.
ProTom International Inc has received 510(k) clearance for its Radiance 330 Proton Therapy System. The Radiance 330 is a compact, modular and more affordable proton beam delivery system for the treatment of patients with cancer. The system delivers extremely focused, conformal, scanned proton beams that destroy tumors while sparing nearby healthy tissue and anatomical structures.
Initial acceptance test results of ProTom International Inc.'s Radiance 330 Proton Therapy System are exceeding expectations of medical physicists charged with clinical commissioning at the McLaren Proton Therapy Center (MPTC) in Flint, Michigan.
Physicists at the McLaren Proton Therapy Center (MPTC) in Flint, Michigan conducted clinical testing of ProTom International, Inc.’s Radiance 330 Proton Therapy System.
Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice.